Investigating this effect further in a mouse model of pancreatic ductal adenocarcinoma (PDAC), Nywening et al. found that combining CCR2 inhibition with CXCR2 inhibition led to a reduction in tumor growth and an increase in tumor-infiltrating lymphocytes [93]. Here, CXCR2 is linked to pancreatic ductal adenocarcinoma.